Log In
BCIQ
Print this Print this
 

Melligen cells

  Manage Alerts
Collapse Summary General Information
Company PharmaCyte Biotech Inc.
DescriptionCells genetically modified to comprise pancreatic islet glucokinase and capable of producing insulin in a glucose responsive manner
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationDiabetes
Indication DetailsTreat Type I diabetes
Regulatory Designation
PartnerUniversity of Technology Sydney

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2.8M

0

$2.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/16/2014

$2.8M

0

$2.8M

Get a free BioCentury trial today